Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Clinical trial NCT03452228 · COMPLETED
Trial details
- NCT number
- NCT03452228
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-07
- Primary completion
- 2019-12-17
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.